Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE
Most relevant news about MERCK AND COMPANY
09/20MERCK : Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudi..
BU
09/20MERCK AND : Publishes Corporate Responsibility Report
PR
09/19ASTELLAS PHARMA : Announces Launch of Dafclir Tablets for the Treatment of Infec..
AQ
09/18DOW MOVERS : Dis, aapl
AQ
09/14MERCK AND : FDA Grants Priority Review to Merck's Application for KEYTRUDA Monot..
AQ
09/14MERCK AND COMPANY : Ex-dividend day for
FA
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13MERCK AND : ZERBAXA Met Primary Endpoints of Non-Inferiority Compared to Meropen..
AQ
09/13BIOCENTURY - MANAGEMENT TRACKS : Clearside, ImCheck
AQ
09/12MERCK AND : European Commission Approves Merck's KEYTRUDA in Combination with Pe..
AQ
09/12MERCK AND : FDA Grants Priority Review to Merck’s Application for KEYTRUDA..
BU
09/11MERCK AND : to Present at the Morgan Stanley 16th Annual Global Healthcare Confe..
AQ
09/11MERCK AND : to Seek Regulatory Approval for Zerbaxa Indication
DJ
09/11MERCK AND : ZERBAXA® (ceftolozane and tazobactam) Met Primary Endpoints of Non-I..
BU
09/10MERCK AND : European Commission Approves Merck’s KEYTRUDA® (pembrolizumab)..
BU
More most relevant news
All news about MERCK AND COMPANY
09/21MERCK FOLLOWS OPDIVOS SUIT, PRICES K : report
AQ
09/20MERCK : Receives Positive CHMP Opinion for DELSTRIGO™ (doravirine/lamivudi..
BU
09/20MERCK AND : Publishes Corporate Responsibility Report
PR
09/19ASTELLAS PHARMA : Announces Launch of Dafclir Tablets for the Treatment of Infec..
AQ
09/18DOW MOVERS : Dis, aapl
AQ
09/14MERCK AND : FDA Grants Priority Review to Merck's Application for KEYTRUDA Monot..
AQ
09/14MERCK AND COMPANY : Ex-dividend day for
FA
09/13Roche steps up efficiency drive to take sting out of biosimilars
RE
09/13MERCK AND : ZERBAXA Met Primary Endpoints of Non-Inferiority Compared to Meropen..
AQ
09/13BIOCENTURY - MANAGEMENT TRACKS : Clearside, ImCheck
AQ
More news
Sector news : Pharmaceuticals - NEC
05:43pASTRAZENECA : EU Grants Marketing Authorization to AstraZeneca's Imfinzi
DJ
01:48pALEXION PHARMACEUTICALS : Soliris Meets Main Endpoint in Central Nervous System ..
DJ
08:30aASTRAZENECA : Mixed Results from Farxiga Trial
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
03:05aAs China builds biotech sector, cash floods U.S. startups
RE
09/23ASTRAZENECA CEO WARNS OF MEDICINE SH : Sunday Times
RE
More sector news : Pharmaceuticals - NEC
Official Publications
08/06Report 
08/02Report 
08/01Report 
07/27Half-year results 
07/24Dividends 
07/02Report 
More Official Publications
News from SeekingAlpha
04:02pExpress Scripts taking credit for Gilead's planned launch of generic HCV meds 
01:47pYOUR DAILY PHARMA SCOOP : Galectin Proceeds, Minerva Rally, Daiichi's New Study 
08:42aGilead to launch generic versions of Epclusa and Harvoni 
09/23The Dogs Of The Dow September Update By Dividend Dogcatcher 
09/22STOCKS TO WATCH : Calling Up Animal Spirits 
09/21Sutro Biopharma Prepares Terms For $75 Million U.S. IPO 
Latest Tweets
07:12p$OPGN here is the chart. ADX is gaining momentum again + partnership with MER..
1
04:34p$OPGN my buy order was finally filled. Great news this morning  
04:25pSantora helped develop Merck’s Fosamax, one of the world's most prescribed os.. 
04:12pOpGen Partnering with New York State Department of Health and Merck’s ILÚM He.. 
04:09pThis underscores the upper hand $MRK has vs $RHHBY in the 1L NSCLC Alimta com..
4
More tweets
Qtime:345
Financials ($)
Sales 2018 42 371 M
EBIT 2018 13 742 M
Net income 2018 7 016 M
Debt 2018 14 978 M
Yield 2018 2,74%
P/E ratio 2018 27,54
P/E ratio 2019 18,57
EV / Sales 2018 4,82x
EV / Sales 2019 4,57x
Capitalization 189 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 73,0 $
Spread / Average Target 2,7%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY26.36%189 092
JOHNSON & JOHNSON2.26%383 312
PFIZER21.65%258 285
NOVARTIS-0.63%216 108
ROCHE HOLDING LTD.-4.60%211 501
AMGEN17.94%132 756